GB0906579D0 - Pharmaceuticals, compositions and methods of making and using the same - Google Patents

Pharmaceuticals, compositions and methods of making and using the same

Info

Publication number
GB0906579D0
GB0906579D0 GBGB0906579.8A GB0906579A GB0906579D0 GB 0906579 D0 GB0906579 D0 GB 0906579D0 GB 0906579 A GB0906579 A GB 0906579A GB 0906579 D0 GB0906579 D0 GB 0906579D0
Authority
GB
United Kingdom
Prior art keywords
making
methods
compositions
compounds
pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0906579.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Priority to GBGB0906579.8A priority Critical patent/GB0906579D0/en
Publication of GB0906579D0 publication Critical patent/GB0906579D0/en
Priority to PL09769578T priority patent/PL2321321T3/pl
Priority to CN200980124230.6A priority patent/CN102076692B/zh
Priority to US12/997,721 priority patent/US8450328B2/en
Priority to AT09769578T priority patent/ATE544767T1/de
Priority to BRPI0910182A priority patent/BRPI0910182B8/pt
Priority to KR1020117001954A priority patent/KR101680390B1/ko
Priority to KR1020167026831A priority patent/KR20160116054A/ko
Priority to NZ590590A priority patent/NZ590590A/en
Priority to PCT/GB2009/001605 priority patent/WO2009156737A1/en
Priority to ES09769578T priority patent/ES2382154T3/es
Priority to PT09769578T priority patent/PT2321321E/pt
Priority to MX2010013841A priority patent/MX2010013841A/es
Priority to JP2011515594A priority patent/JP5559162B2/ja
Priority to DK09769578.7T priority patent/DK2321321T3/da
Priority to KR1020187031734A priority patent/KR102008640B1/ko
Priority to EA201100079A priority patent/EA018803B1/ru
Priority to CA2727444A priority patent/CA2727444C/en
Priority to EP09769578A priority patent/EP2321321B1/en
Priority to AU2009263976A priority patent/AU2009263976B2/en
Priority to IL210071A priority patent/IL210071A/en
Priority to ZA2011/00526A priority patent/ZA201100526B/en
Priority to US13/889,921 priority patent/US8987279B2/en
Priority to US14/618,829 priority patent/US9376443B2/en
Priority to IL243574A priority patent/IL243574B/en
Priority to US15/172,126 priority patent/US9765080B2/en
Priority to US15/682,346 priority patent/US10106547B2/en
Priority to US16/132,411 priority patent/US10538526B2/en
Priority to US16/700,160 priority patent/US10875868B2/en
Priority to US17/088,325 priority patent/US11466019B2/en
Priority to US17/895,037 priority patent/US20230100842A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
GBGB0906579.8A 2008-06-25 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same Ceased GB0906579D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB0906579.8A GB0906579D0 (en) 2009-04-16 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same
CA2727444A CA2727444C (en) 2008-06-25 2009-06-25 Triazolo [4,5-d] pyramidine derivatives and their use as purine receptor antagonists
DK09769578.7T DK2321321T3 (da) 2008-06-25 2009-06-25 Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
KR1020187031734A KR102008640B1 (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
US12/997,721 US8450328B2 (en) 2008-06-25 2009-06-25 Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists
AT09769578T ATE544767T1 (de) 2008-06-25 2009-06-25 Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
BRPI0910182A BRPI0910182B8 (pt) 2008-06-25 2009-06-25 composto de fórmula (i), composição farmacêutica e uso de um composto
KR1020117001954A KR101680390B1 (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
KR1020167026831A KR20160116054A (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
NZ590590A NZ590590A (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyrimidine derivatives and their use as purine receptor antagonists
PCT/GB2009/001605 WO2009156737A1 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
ES09769578T ES2382154T3 (es) 2008-06-25 2009-06-25 Derivados de triazolo [4,5-D]piramidina y su uso como antagonistas de los receptores de purina
PT09769578T PT2321321E (pt) 2008-06-25 2009-06-25 Derivados de triazolo[4,5-d]piramidina e seu uso como anatagonistas do receptor purina
MX2010013841A MX2010013841A (es) 2008-06-25 2009-06-25 Derivados de triazolo[4,5-d]pirimidina y su uso como antagonistas del receptor de purina.
JP2011515594A JP5559162B2 (ja) 2008-06-25 2009-06-25 プリン受容体アンタゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン誘導体およびその使用
PL09769578T PL2321321T3 (pl) 2008-06-25 2009-06-25 Pochodne triazolo [4,5-d]pirymidyny i ich zastosowanie jako antagoniści receptora purynowego
EA201100079A EA018803B1 (ru) 2008-06-25 2009-06-25 Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
AU2009263976A AU2009263976B2 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
CN200980124230.6A CN102076692B (zh) 2008-06-25 2009-06-25 三唑并[4，5-d]嘧啶衍生物及其作为嘌呤受体拮抗剂的应用
EP09769578A EP2321321B1 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d]pyramidine derivatives and their use as purine receptor antagonists
IL210071A IL210071A (en) 2008-06-25 2010-12-16 Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
ZA2011/00526A ZA201100526B (en) 2008-06-25 2011-01-20 Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
US13/889,921 US8987279B2 (en) 2008-06-25 2013-05-08 Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists
US14/618,829 US9376443B2 (en) 2008-06-25 2015-02-10 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
IL243574A IL243574B (en) 2008-06-25 2016-01-11 A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
US15/172,126 US9765080B2 (en) 2008-06-25 2016-06-02 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US15/682,346 US10106547B2 (en) 2008-06-25 2017-08-21 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US16/132,411 US10538526B2 (en) 2008-06-25 2018-09-15 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US16/700,160 US10875868B2 (en) 2008-06-25 2019-12-02 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US17/088,325 US11466019B2 (en) 2008-06-25 2020-11-03 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US17/895,037 US20230100842A1 (en) 2009-04-06 2022-08-24 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0906579.8A GB0906579D0 (en) 2009-04-16 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
GB0906579D0 true GB0906579D0 (en) 2009-05-20

Family

ID=40750727

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0906579.8A Ceased GB0906579D0 (en) 2008-06-25 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same

Country Status (20)

Country Link
US (9) US8450328B2 (enExample)
EP (1) EP2321321B1 (enExample)
JP (1) JP5559162B2 (enExample)
KR (3) KR20160116054A (enExample)
CN (1) CN102076692B (enExample)
AT (1) ATE544767T1 (enExample)
AU (1) AU2009263976B2 (enExample)
BR (1) BRPI0910182B8 (enExample)
CA (1) CA2727444C (enExample)
DK (1) DK2321321T3 (enExample)
EA (1) EA018803B1 (enExample)
ES (1) ES2382154T3 (enExample)
GB (1) GB0906579D0 (enExample)
IL (2) IL210071A (enExample)
MX (1) MX2010013841A (enExample)
NZ (1) NZ590590A (enExample)
PL (1) PL2321321T3 (enExample)
PT (1) PT2321321E (enExample)
WO (1) WO2009156737A1 (enExample)
ZA (1) ZA201100526B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CN104363908B (zh) * 2012-05-30 2017-12-22 霍夫曼-拉罗奇有限公司 吡咯烷基杂环类
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EP3481869A4 (en) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
JP2019536460A (ja) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ−ｔ細胞の調節方法
MX389798B (es) * 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
US10654825B2 (en) * 2017-03-30 2020-05-19 Corvus Pharmaceuticals, Inc. Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
US20190022096A1 (en) * 2017-04-04 2019-01-24 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187484A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080976A1 (en) * 2017-11-06 2019-05-09 Corvus Pharmaceuticals, Inc. Adenosine pathway inhibitors for cancer treatment
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3520782A3 (en) 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CN111615389A (zh) * 2018-02-01 2020-09-01 科尔沃斯制药股份有限公司 药物调配物
CN111511745B (zh) * 2018-02-06 2022-05-27 江苏恒瑞医药股份有限公司 吡唑并[1，5-a][1，3，5]三嗪-2-胺类衍生物、其制备方法及其应用
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102767594B1 (ko) 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
WO2020014666A1 (en) 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
WO2020068583A1 (en) * 2018-09-27 2020-04-02 Corvus Pharmaceuticals, Inc. Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof
WO2020065036A1 (en) 2018-09-27 2020-04-02 Iteos Therapeutics S.A. Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist
BE1026612B1 (fr) 2018-09-27 2020-07-02 Iteos Therapeutics S A Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN119569895A (zh) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
JP2022507734A (ja) * 2018-11-20 2022-01-18 メルク・シャープ・アンド・ドーム・コーポレーション 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EA202192103A1 (ru) 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CA3151078A1 (en) 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
KR20210061202A (ko) * 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
CN114901640A (zh) * 2019-12-24 2022-08-12 兹杜斯生命科学有限公司 适用于治疗血脂异常的新型化合物
WO2021170797A1 (en) 2020-02-26 2021-09-02 iTeos Belgium SA PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS
MX2022012558A (es) 2020-04-07 2023-02-22 iTeos Belgium SA Derivados de diaminas macrocíclicas como inhibidores de ent para el tratamiento de cánceres y combinación de estos con antagonistas del receptor de adenosina.
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022178135A1 (en) 2021-02-17 2022-08-25 Iteos Belguim Sa Compounds, compositions and methods of treatment thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
EP4565262A2 (en) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
US20260207667A1 (en) 2022-12-13 2026-07-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024134541A1 (en) 2022-12-20 2024-06-27 iTeos Belgium SA Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers
TW202523332A (zh) 2023-11-14 2025-06-16 比利時商艾托斯比利時公司 Ｅｎｔ１抑制劑與檢查點抑制劑組合
WO2025170158A1 (ko) * 2024-02-08 2025-08-14 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56131587A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS56131586A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS5962595A (ja) 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５，７―トリ置換―トリアゾロピリミジン誘導体
DE3304330A1 (de) 1983-02-09 1984-08-09 Basf Ag, 6700 Ludwigshafen Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung
JPS60140335A (ja) 1983-12-28 1985-07-25 Konishiroku Photo Ind Co Ltd 熱現像カラ−感光材料
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
NZ274978A (en) 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
WO1997003084A1 (en) 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
EP0994860A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
DE19736535C1 (de) 1997-08-22 1999-01-28 Basf Coatings Ag Basislackzusammensetzung sowie Verfahren zur Herstellung von mehrschichtigen Überzügen
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
US6197788B1 (en) 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6579868B1 (en) 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
WO2001002400A1 (en) 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
WO2007125321A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same

Also Published As

Publication number Publication date
US20110172252A1 (en) 2011-07-14
KR20180122482A (ko) 2018-11-12
KR101680390B1 (ko) 2016-11-28
AU2009263976B2 (en) 2013-12-05
ZA201100526B (en) 2012-04-25
NZ590590A (en) 2011-12-22
CA2727444A1 (en) 2009-12-30
PT2321321E (pt) 2012-05-15
US20170342081A1 (en) 2017-11-30
US20230100842A1 (en) 2023-03-30
JP2011525898A (ja) 2011-09-29
US10875868B2 (en) 2020-12-29
IL210071A0 (en) 2011-02-28
EP2321321B1 (en) 2012-02-08
US8987279B2 (en) 2015-03-24
IL243574B (en) 2019-03-31
KR20110057122A (ko) 2011-05-31
PL2321321T3 (pl) 2012-07-31
ES2382154T3 (es) 2012-06-05
EA018803B1 (ru) 2013-10-30
EP2321321A1 (en) 2011-05-18
EA201100079A1 (ru) 2011-08-30
KR102008640B1 (ko) 2019-08-07
DK2321321T3 (da) 2012-05-21
AU2009263976A1 (en) 2009-12-30
BRPI0910182B8 (pt) 2021-05-25
US9376443B2 (en) 2016-06-28
CA2727444C (en) 2017-01-17
US8450328B2 (en) 2013-05-28
US20150291602A1 (en) 2015-10-15
US20130245044A1 (en) 2013-09-19
US10106547B2 (en) 2018-10-23
WO2009156737A1 (en) 2009-12-30
US20210115054A1 (en) 2021-04-22
US11466019B2 (en) 2022-10-11
MX2010013841A (es) 2011-02-25
US20200172547A1 (en) 2020-06-04
ATE544767T1 (de) 2012-02-15
US20190031668A1 (en) 2019-01-31
US20170088552A1 (en) 2017-03-30
BRPI0910182A2 (pt) 2017-05-30
CN102076692B (zh) 2014-10-22
US9765080B2 (en) 2017-09-19
US10538526B2 (en) 2020-01-21
JP5559162B2 (ja) 2014-07-23
BRPI0910182B1 (pt) 2020-10-27
CN102076692A (zh) 2011-05-25
KR20160116054A (ko) 2016-10-06
IL210071A (en) 2016-02-29

Similar Documents

Publication Publication Date Title
IL243574B (en) A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN02177A (enExample)
IN2012DN00754A (enExample)
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
CA2871471C (en) Dna-pk inhibitors
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
TN2013000529A1 (en) Trpm8 antagonists and their use in treatments
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
NZ703448A (en) Benzimidazole-proline derivatives
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)